In both immortalized astrocytes and glioma cells, IDH1 mutation and ATRX deficiency together lead to similar levels of PARP inhibitor sensitivity compared to the individual mutations, suggesting an epistatic interaction. This evidence concerns the gene IDH1 and central nervous system cancer.